(KVUE) Kenvue - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US49177J1025
Self Care Products, Skin Care, Beauty Items, Oral Care, Baby Care
Dividends
| Dividend Yield | 4.88% |
| Yield on Cost 5y | 3.39% |
| Yield CAGR 5y | 102.50% |
| Payout Consistency | 100.0% |
| Payout Ratio | 82.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 27.7% |
| Value at Risk 5%th | 40.6% |
| Relative Tail Risk | -10.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.74 |
| Alpha | -31.68 |
| CAGR/Max DD | -0.30 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.403 |
| Beta | 0.239 |
| Beta Downside | 0.308 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.08% |
| Mean DD | 19.47% |
| Median DD | 18.43% |
Description: KVUE Kenvue December 03, 2025
Kenvue Inc. (NYSE:KVUE) is a global consumer-health company headquartered in Summit, New Jersey. It sells over-the-counter (OTC) and personal-care products across three segments: Self Care (e.g., Tylenol, Motrin, Benadryl, Nicorette), Skin Health & Beauty (e.g., Neutrogena, Aveeno, Rogaine), and Essential Health (e.g., Listerine, Johnson’s, Band-Aid). The firm operates in North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America.
In FY 2023 Kenvue reported net sales of roughly $16.5 billion, with the Self Care segment contributing about 55 % of revenue and delivering an operating margin near 15 %. Growth is being driven by rising demand for OTC remedies amid an aging population and continued consumer shift toward self-managed health, while inflationary pressure on raw-material costs remains a key risk. The personal-care sector is also benefitting from increased e-commerce penetration, which has accelerated product-mix optimization and margin expansion.
For a deeper, data-rich view of KVUE’s valuation dynamics, you might find ValueRay’s analyst toolkit worth a look.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.43b TTM) > 0 and > 6% of Revenue (6% = 900.4m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 0.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.83% (prev -0.03%; Δ -0.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 2.14b > Net Income 1.43b (YES >=105%, WARN >=100%) |
| Net Debt (7.97b) to EBITDA (2.94b) ratio: 2.71 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.92b) change vs 12m ago -0.05% (target <= -2.0% for YES) |
| Gross Margin 58.14% (prev 57.78%; Δ 0.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.40% (prev 57.42%; Δ -2.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.22 (EBITDA TTM 2.94b / Interest Expense TTM 455.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.21
| (A) -0.00 = (Total Current Assets 6.03b - Total Current Liabilities 6.16b) / Total Assets 27.25b |
| (B) -0.00 = Retained Earnings (Balance) -136.0m / Total Assets 27.25b |
| (C) 0.09 = EBIT TTM 2.37b / Avg Total Assets 27.09b |
| (D) -0.32 = Book Value of Equity -5.25b / Total Liabilities 16.61b |
| Total Rating: 0.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.82
| 1. Piotroski 5.50pt |
| 2. FCF Yield 3.97% |
| 3. FCF Margin 10.92% |
| 4. Debt/Equity 0.86 |
| 5. Debt/Ebitda 2.71 |
| 6. ROIC - WACC (= 3.89)% |
| 7. RoE 13.95% |
| 8. Rev. Trend 18.55% |
| 9. EPS Trend -32.87% |
What is the price of KVUE shares?
As of December 06, 2025, the stock is trading at USD 16.93 with a total of 21,148,108 shares traded.
Over the past week, the price has changed by -2.42%, over one month by +5.62%, over three months by -7.93% and over the past year by -23.77%.
Over the past week, the price has changed by -2.42%, over one month by +5.62%, over three months by -7.93% and over the past year by -23.77%.
Is KVUE a buy, sell or hold?
Kenvue has received a consensus analysts rating of 3.42.
Therefor, it is recommend to hold KVUE.
- Strong Buy: 3
- Buy: 2
- Hold: 14
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KVUE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.3 | 14.2% |
| Analysts Target Price | 19.3 | 14.2% |
| ValueRay Target Price | 18.1 | 6.7% |
KVUE Fundamental Data Overview December 02, 2025
Market Cap USD = 33.30b (33.30b USD * 1.0 USD.USD)
P/E Trailing = 23.1333
P/E Forward = 15.7729
P/S = 2.2188
P/B = 3.1257
P/EG = 0.8861
Beta = 0.658
Revenue TTM = 15.01b USD
EBIT TTM = 2.37b USD
EBITDA TTM = 2.94b USD
Long Term Debt = 7.06b USD (from longTermDebt, last quarter)
Short Term Debt = 1.95b USD (from shortTermDebt, last quarter)
Debt = 9.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.97b USD (from netDebt column, last quarter)
Enterprise Value = 41.27b USD (33.30b + Debt 9.11b - CCE 1.14b)
Interest Coverage Ratio = 5.22 (Ebit TTM 2.37b / Interest Expense TTM 455.0m)
FCF Yield = 3.97% (FCF TTM 1.64b / Enterprise Value 41.27b)
FCF Margin = 10.92% (FCF TTM 1.64b / Revenue TTM 15.01b)
Net Margin = 9.55% (Net Income TTM 1.43b / Revenue TTM 15.01b)
Gross Margin = 58.14% ((Revenue TTM 15.01b - Cost of Revenue TTM 6.28b) / Revenue TTM)
Gross Margin QoQ = 59.14% (prev 58.90%)
Tobins Q-Ratio = 1.51 (Enterprise Value 41.27b / Total Assets 27.25b)
Interest Expense / Debt = 1.02% (Interest Expense 93.0m / Debt 9.11b)
Taxrate = 24.33% (128.0m / 526.0m)
NOPAT = 1.80b (EBIT 2.37b * (1 - 24.33%))
Current Ratio = 0.98 (Total Current Assets 6.03b / Total Current Liabilities 6.16b)
Debt / Equity = 0.86 (Debt 9.11b / totalStockholderEquity, last quarter 10.63b)
Debt / EBITDA = 2.71 (Net Debt 7.97b / EBITDA 2.94b)
Debt / FCF = 4.86 (Net Debt 7.97b / FCF TTM 1.64b)
Total Stockholder Equity = 10.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.26% (Net Income 1.43b / Total Assets 27.25b)
RoE = 13.95% (Net Income TTM 1.43b / Total Stockholder Equity 10.27b)
RoCE = 13.69% (EBIT 2.37b / Capital Employed (Equity 10.27b + L.T.Debt 7.06b))
RoIC = 9.48% (NOPAT 1.80b / Invested Capital 18.95b)
WACC = 5.58% (E(33.30b)/V(42.40b) * Re(6.90%) + D(9.11b)/V(42.40b) * Rd(1.02%) * (1-Tc(0.24)))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.21%
[DCF Debug] Terminal Value 75.41% ; FCFE base≈1.54b ; Y1≈1.29b ; Y5≈962.1m
Fair Price DCF = 9.22 (DCF Value 17.67b / Shares Outstanding 1.92b; 5y FCF grow -19.65% → 3.0% )
EPS Correlation: -32.87 | EPS CAGR: -1.54% | SUE: -0.66 | # QB: 0
Revenue Correlation: 18.55 | Revenue CAGR: 0.22% | SUE: -0.75 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.26 | Chg30d=-0.003 | Revisions Net=-4 | Analysts=6
EPS next Year (2026-12-31): EPS=1.11 | Chg30d=-0.011 | Revisions Net=-3 | Growth EPS=+7.1% | Growth Revenue=+2.8%
P/E Trailing = 23.1333
P/E Forward = 15.7729
P/S = 2.2188
P/B = 3.1257
P/EG = 0.8861
Beta = 0.658
Revenue TTM = 15.01b USD
EBIT TTM = 2.37b USD
EBITDA TTM = 2.94b USD
Long Term Debt = 7.06b USD (from longTermDebt, last quarter)
Short Term Debt = 1.95b USD (from shortTermDebt, last quarter)
Debt = 9.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.97b USD (from netDebt column, last quarter)
Enterprise Value = 41.27b USD (33.30b + Debt 9.11b - CCE 1.14b)
Interest Coverage Ratio = 5.22 (Ebit TTM 2.37b / Interest Expense TTM 455.0m)
FCF Yield = 3.97% (FCF TTM 1.64b / Enterprise Value 41.27b)
FCF Margin = 10.92% (FCF TTM 1.64b / Revenue TTM 15.01b)
Net Margin = 9.55% (Net Income TTM 1.43b / Revenue TTM 15.01b)
Gross Margin = 58.14% ((Revenue TTM 15.01b - Cost of Revenue TTM 6.28b) / Revenue TTM)
Gross Margin QoQ = 59.14% (prev 58.90%)
Tobins Q-Ratio = 1.51 (Enterprise Value 41.27b / Total Assets 27.25b)
Interest Expense / Debt = 1.02% (Interest Expense 93.0m / Debt 9.11b)
Taxrate = 24.33% (128.0m / 526.0m)
NOPAT = 1.80b (EBIT 2.37b * (1 - 24.33%))
Current Ratio = 0.98 (Total Current Assets 6.03b / Total Current Liabilities 6.16b)
Debt / Equity = 0.86 (Debt 9.11b / totalStockholderEquity, last quarter 10.63b)
Debt / EBITDA = 2.71 (Net Debt 7.97b / EBITDA 2.94b)
Debt / FCF = 4.86 (Net Debt 7.97b / FCF TTM 1.64b)
Total Stockholder Equity = 10.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.26% (Net Income 1.43b / Total Assets 27.25b)
RoE = 13.95% (Net Income TTM 1.43b / Total Stockholder Equity 10.27b)
RoCE = 13.69% (EBIT 2.37b / Capital Employed (Equity 10.27b + L.T.Debt 7.06b))
RoIC = 9.48% (NOPAT 1.80b / Invested Capital 18.95b)
WACC = 5.58% (E(33.30b)/V(42.40b) * Re(6.90%) + D(9.11b)/V(42.40b) * Rd(1.02%) * (1-Tc(0.24)))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.21%
[DCF Debug] Terminal Value 75.41% ; FCFE base≈1.54b ; Y1≈1.29b ; Y5≈962.1m
Fair Price DCF = 9.22 (DCF Value 17.67b / Shares Outstanding 1.92b; 5y FCF grow -19.65% → 3.0% )
EPS Correlation: -32.87 | EPS CAGR: -1.54% | SUE: -0.66 | # QB: 0
Revenue Correlation: 18.55 | Revenue CAGR: 0.22% | SUE: -0.75 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.26 | Chg30d=-0.003 | Revisions Net=-4 | Analysts=6
EPS next Year (2026-12-31): EPS=1.11 | Chg30d=-0.011 | Revisions Net=-3 | Growth EPS=+7.1% | Growth Revenue=+2.8%
Additional Sources for KVUE Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle